Immuto Scientific is redefining the landscape of target discovery by revealing the structural fingerprints of disease. Through its therapeutic discovery arm, Immuto is discovering and developing first-in-class therapeutics that target structural changes in cell-surface proteins unique to disease. Powered by its AI-enabled target discovery and epitope-identification platforms, Immuto discovers novel, targetable surface protein conformations (SPCs) from patient-derived samples, driving the development of safer, more precise therapies. With its

disease-agnostic platform, Immuto is building a differentiated pipeline with an initial focus on oncology.